NCT01468285

The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow

A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Abbott Products · Industry
• Sex: All
• Age: 40 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.

Conditions

• Gait or Balance Disorder Problems

Interventions

Type	Name	Description
DRUG	betahistine dihydrochloride	betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
OTHER	placebo	placebo tablets b.i.d., six weeks treatment

Timeline

• Start date: 2012-02-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2011-11-09
• Last updated: 2017-10-26

Locations

2 sites across 1 country: Singapore